A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations

Summary

The primary purpose of this study is to compare the progression-free survival (PFS) in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring human epidermal growth factor receptor 2 (HER2) exon 20 mutations when treated with poziotinib versus docetaxel.

Timeline

Start

2022-05-12

Primary completion

2027-12-25

Completion

2028-12-25

Outcome

Outcome not reported

Stopped (Enrollment): “The study has not enrolled any patients. The study design is under discussion and will likely be redesigned in consultation with the FDA.”

Drugs

Indications